Shalby's implant unit turns profit. Gurgaon still can't.
Medical devices posted a second straight profitable quarter. The international hospital has no timeline for breakeven, and the long-term implant target has been cut.
— 1 earlier story on Shalby Ltd. →What's new
- The medical implants division posted its second consecutive quarter of positive EBITDA.
- Management withdrew specific breakeven timelines for the Gurgaon international hospital unit, citing geopolitical disruptions.
- Long-term implant revenue target revised down to ₹600-650 crores by 2030.
Why this matters
The split outcome defines Shalby's current strategy. The core hospital and implants business is improving, but the high-profile international expansion is stalling. The revised implant target and the Gurgaon delay signal a more conservative, capital-focused growth path.
What we're watching
- The Q2 FY27 period flagged by management as the next test for the broader recovery.
- Impact of government rate revisions on hospital revenue in the coming fiscal year.
- Group occupancy trends as the primary driver of near-term profit growth.
The full read
Shalby is two stories. The medical implants division just logged its second consecutive EBITDA-positive quarter. A clear turn. Consolidated EBITDA jumped 43% to ₹37.4 crores on revenue of ₹295.5 crores, driven by manufacturing efficiencies. But the Gurgaon international hospital, once a marquee expansion bet, has no timeline for profitability. Geopolitical disruptions have cut patient flows, and management pulled its breakeven targets. The strategic pivot is explicit: franchise expansion is out. Core hospitals and the scaling implants unit, targeting ₹600-650 crores by 2030, are in. That implant target is a downgrade from prior ambitions, a tacit admission that the growth path is steeper than once thought. Q2 FY27 is the next test. That is when management expects government rate revisions and higher occupancy to lift the broader business, not just the manufacturing line.
Questions answered
- How is the medical implants business performing?
- The division posted its second straight quarter of positive EBITDA, indicating a transition to sustained profitability. Management is targeting ₹600-650 crores in implant revenue by 2030, a more conservative goal than previously outlined.
- What happened with the Gurgaon hospital unit?
- Management withdrew previously stated breakeven timelines for the international hospital. The delay is attributed to geopolitical issues that have reduced the flow of international patients to the facility.
- What is Shalby's new strategic priority?
- The company is deprioritizing franchise expansion to focus on its core mainline hospital operations and the scaling medical implants business. The shift emphasizes capital efficiency over rapid geographic growth.
- What were the headline Q4 financials?
- Consolidated revenue reached ₹295.5 crores. EBITDA grew 43% year-on-year to ₹37.4 crores, driven by manufacturing efficiencies and scale.
- What is the next key milestone to watch?
- Management has flagged the Q2 FY27 period as a critical point for validating its recovery thesis. The timeline aligns with expected tailwinds from government rate revisions.
Story so far
All notes on SHALBY →- 29 May 2026 · 7:42 PM IST Shalby's implant unit turns profit. Gurgaon still can't.
- 3d ago Shalby reports FY26 profit boost driven by tax credits